Abbott Laboratories (ABT): price to earnings, 10 filed years

P/E at Abbott Laboratories was 33.68x in FY2025, the newest filed year. Across the 10 computed years from FY2016 it ranged from 14.80x (FY2024) to 211.37x (FY2017), with a median of 38.29x.

Tonight's figure on the company page: 28.07x, at the close of 2026-10-15, recomputed 2026-10-15. The table is each filed year on its own terms, with the formula below; the current figure may use trailing twelve months or, where the explainer says so, a different denominator.

Year by year

Abbott Laboratories: P/E for each filed fiscal year, with the filing behind each.
Fiscal year	P/E	Close used	Read from
FY2016	40.86x	38.41 on 2016-12-30	10-K, filed 2017-02-17
FY2017	211.37x	57.07 on 2017-12-29	10-K, filed 2018-02-16
FY2018	54.38x	72.33 on 2018-12-31	10-K, filed 2019-02-22
FY2019	42.17x	86.86 on 2019-12-31	10-K, filed 2020-02-21
FY2020	43.80x	109.49 on 2020-12-31	10-K, filed 2021-02-19
FY2021	35.72x	140.74 on 2021-12-31	10-K, filed 2022-02-18
FY2022	28.08x	109.79 on 2022-12-30	10-K, filed 2023-02-17
FY2023	33.76x	110.07 on 2023-12-29	10-K, filed 2024-02-16
FY2024	14.80x	113.11 on 2024-12-31	10-K, filed 2025-02-21
FY2025	33.68x	125.29 on 2025-12-31	10-K, filed 2026-02-20

How each year is computed

Close at fiscal year end / diluted earnings per share

P/E, free cash flow yield and EV to EBIT set each filed year against the close on or within a week before that fiscal year's end. The price archive here is about five years deep, so older years of those three read n/a. Per-share figures and share counts are put on today's share count after a confirmed split, the basis the price archive is kept on.

Read further

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.